C57小鼠源性淋巴瘤的基因枪途径抗肿瘤免疫研究

[目的]诱导C57小鼠建立有效的抗肿瘤免疫.[方法]用基因枪途径给C57小鼠腹部接种含有粒巨噬细胞集落刺激因子(GMCSF)基因的质粒,24h后在同一部位注射FBL3肿瘤细胞破碎后的上清液,15d后用3×106个FBL3肿瘤细胞皮下接种攻击.[结果]肿瘤的生长受到抑制,小鼠的生存时间明显延长.[结论]基因枪途径局部接种含有GMCSF基因的质粒,可增强机体的抗肿瘤免疫,抑制肿瘤细胞的生长.     

恶性肿瘤并发皮肤瘙痒症5例临床分析

作者认为恶性肿瘤引起的瘙痒有二种特点:(1)患者难以忍受;(2)抗组织胺药物无效。     

骨旁脂肪瘤临床影像学表现与病理分析(文献综述附14例报告)

[目的]结合文献探讨骨旁脂肪瘤的命名、病因、临床病理表现和影像学特点。[方法]将国内文献的20例一起列入临床资料分析,包括作者14例共34例术前均行X线摄片,18例行CT检查,4例行MRI检查。[结果]本病发生于任何年龄,成人多见,以四肢长管状骨为好发,其次发生于扁平骨(骨盆、肩岬骨、髌骨、肋骨)、不规则骨(胸椎、腰椎、骶尾椎)、短管状骨和跗骨;本病临床误诊率为41.17%,X线误诊率26.47%,CT及MRI诊断率100%;34例均手术切除,病理报告为脂肪瘤,3例低度恶变;随访2~10年,仅1例复发并恶变。[结论]骨旁脂肪瘤是最佳的命名,病因未明,但与遗传和先天因素及创伤和炎症因素有关;病理表现为带骨蒂的脂肪瘤,细胞学形态为脂肪组织;影像学具有特征性表现。     

乳腺良恶性病变的磁共振T2*W首过灌注成像与血管生成相关性研究

Objective： To study the diagnostic value of T2^＊-weighted first-pass perfusion imaging in breast tumors. Methods： We analyzed the magnetic resonance imaging （MRI） information along with the pathological and immunohistochemistry results. Magnetic resonance imaging was performed in 28 patients with breast tumor. The time to signal intensity curves were generated according to the T2^＊-weighted first-pass perfusion imaging. The curve＇s maximal signal intensity drop rate and maximal signal intensity decrease time were analyzed and compared with the pathological diagnoses after surgery. Results： Malignant breast lesions showed higher maximal signal intensity drop rate （44.69% ± 17.07 vs. 17.22% ±7.49, P 〈 0.001） than benign lesions, but there was no significant difference of maximal signal decrease time between those two lesions （23.94 s ± 4.92 vs. 20.02 s ± 6.83, P 〉 0.05）. Conclusion： The T2^＊-weighted first-pass perfusion imaging has enough sensitivity and specificity in breast tumor diagnosis.     

肝细胞癌合并胆管癌栓患者术中癌栓的处理

目的 探讨肝细胞癌（HCC）合并胆管癌栓患者术中癌栓的处理方式和术后恢复过程。方法 对1995年1月-2002年12月手术治疗的27例HCC合并胆管癌栓情况进行回顾性总结和分析。结果 只有59．3％（16／27）患者行肝切除、胆管取癌栓及胆管引流术。全组术后并发症发生率为55．6％（15／27），术后30d病死率为22．2％（6／27）。结论 HCC合并胆管癌栓的预后差，早期诊断和外科手术治疗是改善此病预后的关键。     

11^C-蛋氨酸的体内生物学分布和初步临床应用

目的研究新型脑肿瘤显像剂：11^C-蛋氨酸（11^C-MET）的体内生物学分布，探讨11^C—MET的临床显像方法及其在脑肿瘤显像中的应用．方法测定11^C—MET在小鼠体内的分布，对健康志愿者和病理证实胶质瘤患者进行PET脑显像．结果小鼠体内分布实验和脑PET显像发现，11^C—MET在血液中清除较慢，在肿瘤内有较长的滞留时问，平台期位于30—45min之间，延迟相对有利于脑瘤的显像，其余放射性主要集中在消化系统．结论11^C—MDT有较高的肿瘤／脑比值，是理想的脑肿瘤显像剂．     

骨外型牙源性钙化上皮瘤1例报告

牙源性钙化上皮瘤是一种良性肿瘤，也称Pindborg瘤，可分为骨内型和骨外型2种，主要发生于颌骨内，偶见于颌骨外。本文报告1例发生于口底的牙源性钙化上皮瘤，其临床症状与口底皮样囊肿相似．术后经组织病理学确诊，主要组织病理学特征是嗜酸性环状钙化团块。因其具有局部侵袭性，为避免复发，提倡完整切除肿物。     

密盖息治疗49例恶性骨转移瘤疗效观察

目的:观察密盖息(鲑鱼降钙素)的治疗骨转移瘤疼痛和血清钙的临床疗效。方法:单用组用密盖息100IU,肌肉注射,每日2次,共7d。联合化疗组化疗后加密盖息100IU肌肉注射,每日2次,每次7d。治疗结束进行疗效评价。结果:单用组骨痛完全缓解66.7%(12/18)。联合化疗组骨痛完全缓解率87.1%(27/31)。单用组血钙降至正常,占77.8%(14/18),联合化疗组血钙完全降至正常占100%(31/31)。副作用是暂时性的心动过速、皮肤潮红、头晕、恶心呕吐,无需特殊处理,自行缓解。结论:密盖息治疗骨转移瘤有止痛、降低血钙作用良好,副作用小,可以在临床上安全使用。     

Repeat Transarterial Chemoembolization (TACE) for Progressive Hepatic Carcinoid Metastases Provides Results Similar to First TACE

Background Transarterial chemoemobolization (TACE) is commonly used to treat metastatic carcinoid tumors; however, the management of progressive disease is less clear. We sought to determine if patients with disease progression after TACE would benefit from repeat TACE. Methods The records of 27 patients undergoing repeat TACE for radiologic or symptomatic progression after TACE for metastatic carcinoid were reviewed and compared to 122 undergoing first TACE. Overall and progression-free survivals were estimated by the Kaplan–Meier method. Results Mean disease-free interval after first TACE was 11.8 months. Radiologic response was observed in 61% compared to 82% after first TACE (p = 0.058); hormone response in 64% compared to 80% (p = 0.159); and symptomatic response in 77% compared to 92% (p = 0.053). The complication rate after repeat TACE was lower than after first TACE (p = 0.03). Median overall survival was similar after repeat (28.1 months) and first TACE (33.3 months) (p = 0.53). Progression-free survival was shorter after repeat TACE but not significantly so. No factor examined could predict survival after repeat TACE. Conclusion Repeat TACE for patients with hepatic carcinoid metastases failing first TACE or having evidence of disease progression is safe and offers a viable treatment option. Presented at the 48th Annual Meeting of The Society for Surgery of the Alimentary Tract, Washington, DC, May, 2007.